Annexin A4 N-terminal peptide inhibits adenylyl cyclase 5 and limits β-adrenoceptor-mediated prolongation of cardiac action potential.
Action Potentials
/ physiology
Adenylyl Cyclases
/ metabolism
Animals
Annexin A4
/ metabolism
Calcium Channels, L-Type
/ metabolism
Cell Line
Cyclic AMP
/ metabolism
HEK293 Cells
Heart
/ physiology
Humans
Male
Mice
Muscle Cells
/ metabolism
Myocytes, Cardiac
/ metabolism
Receptors, Adrenergic
/ metabolism
FRET
calcium current
cardiomyocytes
co-immunoprecipitation
cyclic AMP
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
19
08
2019
revised:
08
05
2020
accepted:
26
05
2020
pubmed:
25
6
2020
medline:
2
3
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Adenylyl cyclases (AC) are essential for the normal and pathophysiological response of many cells. In cardiomyocytes, the predominant AC isoforms are AC5 and AC6. Specific AC5 inhibition was suggested as an option for the treatment of heart failure potentially advantageous over β-blockers. We previously reported an interaction between the calcium-binding protein annexin A4 (ANXA4) and AC5 in human embryonic kidney 293 (HEK293) cells and an inhibition of cyclic adenosine monophosphate (cAMP) production in cardiomyocytes. Here, we investigated whether ANXA4 is able to differentiate between AC5 and AC6. In transfected HEK293 cells, ANXA4 specifically co-immunoprecipitated with AC5 and not with AC6, via its N-terminal domain. Both ANXA4 and a peptide comprising the ANXA4 N-terminal sequence (A4N
Identifiants
pubmed: 32579290
doi: 10.1096/fj.201902094RR
doi:
Substances chimiques
Annexin A4
0
Calcium Channels, L-Type
0
Receptors, Adrenergic
0
Cyclic AMP
E0399OZS9N
Adenylyl Cyclases
EC 4.6.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10489-10504Informations de copyright
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Pieske B. Reverse remodeling in heart failure-fact or fiction? Eur Heart J Suppl. 2004;6:D66-D78.
DeGeorge BR Jr, Koch WJ. Beta blocker specificity: a building block toward personalized medicine. J Clin Invest. 2007;117:86-89.
Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. New Engl J Med. 2002;346:1357-1365.
Baldwin TA, Dessauer CW. Function of adenylyl cyclase in heart: the AKAP connection. J Cardiovasc Dev Dis. 2018;5:2.
Guellich A, Mehel H, Fischmeister R. Cyclic AMP synthesis and hydrolysis in the normal and failing heart. Pflugers Arch. 2014;466:1163-1175.
Okumura S, Vatner DE, Kurotani R, et al. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation. 2007;116:1776-1783.
Okumura S, Takagi G, Kawabe J, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA. 2003;100:9986-9990.
Tang T, Lai NC, Hammond HK, et al. Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice. J Am Coll Cardiol. 2010;55:1476-1486.
Zhao Z, Babu GJ, Wen H, et al. Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart. Am J Physiol Heart Circ Physiol. 2015;308:H240-249.
Lai L, Yan L, Gao S, et al. Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway. Circulation. 2013;127:1692-1701.
Guellich A, Gao S, Hong C, et al. Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload. Am J Physiol Heart Circ Physiol. 2010;299:H707-712.
Sugano Y, Lai NC, Gao MH, et al. Activated expression of cardiac adenylyl cyclase 6 reduces dilation and dysfunction of the pressure-overloaded heart. Biochem Biophys Res Comm. 2011;405:349-355.
Vatner SF, Park M, Yan L, et al. Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging. Am J Physiol Heart Circ Physiol. 2013;305:H1-H8.
Heinick A, Husser X, Himmler K, et al. Annexin A4 is a novel direct regulator of adenylyl cyclase type 5. FASEB J. 2015;29:3773-3787.
Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6:449-461.
Concha NO, Head JF, Kaetzel MA, Dedman JR, Seaton BA. Rat annexin V crystal structure: Ca(2+)-induced conformational changes. Science. 1993;261:1321-1324.
Gunteski-Hamblin AM, Song G, Walsh RA, et al. Annexin VI overexpression targeted to heart alters cardiomyocyte function in transgenic mice. Am J Physiol. 1996;270:H1091-1100.
Herr C, Smyth N, Ullrich S, et al. Loss of annexin A7 leads to alterations in frequency-induced shortening of isolated murine cardiomyocytes. Mol Cell Biol. 2001;21:4119-4128.
Diaz-Munoz M, Hamilton SL, Kaetzel MA, Hazarika P, Dedman JR. Modulation of Ca2+ release channel activity from sarcoplasmic reticulum by annexin VI (67-kDa calcimedin). J Biol Chem. 1990;265:15894-15899.
Sobota A, Cusinato F, Luciani S. Identification and purification of calpactins from cardiac muscle and their effect on Na+/Ca2+ exchange activity. Biochem Biophys Res Comm. 1990;172:1067-1072.
Camors E, Monceau V, Charlemagne D. Annexins and Ca2+ handling in the heart. Cardiovasc Res. 2005;65:793-802.
Song G, Campos B, Wagoner LE, Dedman JR, Walsh RA. Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. J Mol Cell Cardiol. 1998;30:443-451.
Matteo RG, Moravec CS. Immunolocalization of annexins IV, V and VI in the failing and non-failing human heart. Cardiovasc Res. 2000;45:961-970.
Ravassa S, Gonzalez A, Lopez B, et al. Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J. 2007;28:2785-2791.
Trouve P, Legot S, Belikova I, et al. Localization and quantitation of cardiac annexins II, V, and VI in hypertensive guinea pigs. Am J Physiol. 1999;276:H1159-H1166.
Li B, Dedman JR, Kaetzel MA. Intron disruption of the annexin IV gene reveals novel transcripts. J Biol Chem. 2003;278:43276-43283.
Sadana R, Dessauer CW. Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neuro-Signals. 2009;17:5-22.
Seidl MD, Stein J, Hamer S, et al. Characterization of the genetic program linked to the development of atrial fibrillation in CREM-Ib delta C-X mice. Circ Arrhythm Electrophysiol. 2017;10:e005075.
Pluteanu F, Cribbs LL. T-type calcium channels are regulated by hypoxia/reoxygenation in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2009;297:H1304-H1313.
Ellerkmann RK, Remy S, Chen J, et al. Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience. 2003;119:323-333.
Bers DM. Excitation-contraction coupling and cardiac contractile force. Dordrecht: Kluwer Academic Publishers; 2001.
Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36.
Antoni FA, Wiegand UK, Black J, Simpson J. Cellular localisation of adenylyl cyclase: a post-genome perspective. Neurochem Res. 2006;31:287-295.
Gottle M, Geduhn J, Konig B, Gille A, Hocherl K, Seifert R. Characterization of mouse heart adenylyl cyclase. J Pharmacol Exp Ther. 2009;329:1156-1165.
Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82:331-371.
Piljic A, Schultz C. Annexin A4 self-association modulates general membrane protein mobility in living cells. Mol Biol Cell. 2006;17:3318-3328.
Ayala-Sanmartin J, Zibouche M, Illien F, Vincent M, Gallay J. Insight into the location and dynamics of the annexin A2 N-terminal domain during Ca(2+)-induced membrane bridging. Biochem Biophys Acta. 2008;1778:472-482.
Rety S, Sopkova J, Renouard M, et al. The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nature structural biology. 1999;6:89-95.
Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell. 2000;5:831-840.
Willshaw A, Grant K, Yan J, et al. Identification of a novel protein complex containing annexin A4, rabphilin and synaptotagmin. FEBS Lett. 2004;559:13-21.
Watts VJ, Neve KA. Sensitization of adenylate cyclase by Galpha i/o-coupled receptors. Pharmacol Ther. 2005;106:405-421.
Hawkins TE, Roes J, Rees D, Monkhouse J, Moss SE. Immunological development and cardiovascular function are normal in annexin VI null mutant mice. Mol Cell Biol. 1999;19:8028-8032.
Brachvogel B, Dikschas J, Moch H, et al. Annexin A5 is not essential for skeletal development. Mol Cell Biol. 2003;23:2907-2913.
Babij P, Askew GR, Nieuwenhuijsen B, et al. Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice. Circ Res. 1998;83:668-678.
Lujan HL, Rivers JP, DiCarlo SE. Complex and interacting influences of the autonomic nervous system on cardiac electrophysiology in conscious mice. Auton Neurosci. 2016;201:24-31.
Antoons G, Volders PG, Stankovicova T, et al. Window Ca2+ current and its modulation by Ca2+ release in hypertrophied cardiac myocytes from dogs with chronic atrioventricular block. J Physiol. 2007;579:147-160.
Gao MH, Lai NC, Roth DM, et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation. 1999;99:1618-1622.
Baran I, Varekova RS, Parthasarathi L, Suchomel S, Casey F, Shields DC. Identification of potential small molecule peptidomimetics similar to motifs in proteins. J Chem Inf Model. 2007;47:464-474.
Kim KS, Kim J, Back SK, Im JY, Na HS, Han PL. Markedly attenuated acute and chronic pain responses in mice lacking adenylyl cyclase-5. Genes Brain Behav. 2007;6:120-127.
De Lorenzo MS, Chen W, Baljinnyam E, et al. Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption. Aging Cell. 2014;13:102-110.
Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:942-950.
Hammond HK, Penny WF, Traverse JH, et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 2016;1:163-171.
Penny WF, Henry TD, Watkins MW, Patel AN, Hammond HK. Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial. Am Heart J. 2018;201:111-116.
Schulte JS, Seidl MD, Nunes F, et al. CREB critically regulates action potential shape and duration in the adult mouse ventricle. Am J Physiol Heart Circ Physiol. 2012;302:H1998-H2007.